Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer (COMREC)
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer-a National Multi-center, Prospective, Real World Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yi Xiao, Professor
- Phone Number: +86 13366036387
- Email: Xiaoy@pumch.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Xiao Yi
- Phone Number: +86 13366036387
- Email: xiaoy@pumch.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- pathologically confirmed rectal adenocarcinoma
- located within 12cm below the anal verge
Exclusion Criteria:
- diagnosed with distant metastasis
- multiple primary colorectal cancers
- history of previous malignant tumors
- Pregnant or lactating women
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3-year OS
Time Frame: 3 years
|
3-year overall survival
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3-year DFS
Time Frame: 3 years
|
3-year disease-free survival
|
3 years
|
|
3-year LR
Time Frame: 3 years
|
3-year local recurrence rate
|
3 years
|
|
3-year distant metastasis rate
Time Frame: 3 years
|
3-year distant metastasis rate
|
3 years
|
|
neoadjuvant therapy rate
Time Frame: at the time point of surgery of the primary lesion
|
the percentage of patients who underwent standard neoadjuvant therapy
|
at the time point of surgery of the primary lesion
|
|
adjuvant therapy rate
Time Frame: at the time point of 3-year follow up
|
the percentage of patients who underwent standard adjuvant therapy
|
at the time point of 3-year follow up
|
|
EUS/MRI assessment rate
Time Frame: at the time point of surgery of the primary lesion
|
the percentage of patients who underwent standard rectal EUS/MRI assessment
|
at the time point of surgery of the primary lesion
|
|
R0 resection rate
Time Frame: at the time point of surgery of the primary lesion
|
the percentage of patients who underwent R0 resection
|
at the time point of surgery of the primary lesion
|
|
CCR
Time Frame: immediately after the completion of neoadjuvant therapy assessment
|
Clinical Complete Response
|
immediately after the completion of neoadjuvant therapy assessment
|
|
pCR
Time Frame: immediately after the completion of surgery
|
Pathologic Complete Response
|
immediately after the completion of surgery
|
|
30-day mortality
Time Frame: 30 days after the surgery
|
death occurring within 30 days of the surgery
|
30 days after the surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-PUMCH-C-027
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.